Goldman Sachs
NVO

Goldman Sachs’s Novo Nordisk NVO Stock Holding History

Goldman Sachs’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11M Buy
300,000
+190,000
+173% +$9M ﹤0.01% 2997
2025
Q4 		$5.6M Sell
110,000
-267,400
-71% -$13.7M ﹤0.01% 3653
2025
Q3 		$20.9M Buy
377,400
+317,400
+529% +$18.6M ﹤0.01% 2220
2025
Q2 		$4.14M Sell
60,000
-240,000
-80% -$16.3M ﹤0.01% 3586
2025
Q1 		$20.8M Sell
300,000
-588,400
-66% -$48.6M ﹤0.01% 1989
2024
Q4 		$76.4M Buy
888,400
+772,900
+669% +$83.6M 0.01% 971
2024
Q3 		$13.8M Sell
115,500
-56,700
-33% -$7.56M ﹤0.01% 2405
2024
Q2 		$24.6M Buy
172,200
+52,200
+44% +$6.92M ﹤0.01% 1716
2024
Q1 		$15.4M Sell
120,000
-451,800
-79% -$53.8M ﹤0.01% 2061
2023
Q4 		$59.2M Hold
571,800
– – 0.01% 1072
2023
Q3 		$52M Buy
+571,800
New +$50.4M 0.01% 1078
2021
Q4 		– Sell
-100,000
Closed -$4.8M – 6627
2021
Q3 		$4.8M Buy
+100,000
New +$4.83M ﹤0.01% 3399
2021
Q1 		– Sell
-200,000
Closed -$6.99M – 6261
2020
Q4 		$6.99M Hold
200,000
– – ﹤0.01% 2739
2020
Q3 		$6.94M Buy
+200,000
New +$6.67M ﹤0.01% 2637
2019
Q1 		– Sell
-117,000
Closed -$2.69M – 5349
2018
Q4 		$2.69M Buy
+117,000
New +$2.6M ﹤0.01% 3340
2014
Q2 		– Sell
-45,400
Closed -$1.04M – 7093
2014
Q1 		$1.04M Buy
+45,400
New +$967K ﹤0.01% 4646
2013
Q3 		– Sell
-55,000
Closed -$852K – 6643
2013
Q2 		$852K Buy
+55,000
New +$915K ﹤0.01% 4517

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Goldman Sachs's NVO Position: Q1 2026 in Review

Goldman Sachs reduced its Novo Nordisk (NVO) stake by 53% in Q1 2026, selling an estimated $278M and leaving 5,121,037 shares worth $188M. The position accounts for 0.02% of the portfolio, ranked #707.

Goldman Sachs first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $663M in Q1 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Goldman Sachs held 5,121,037 shares of Novo Nordisk worth $188M as of Q1 2026.
  • Goldman Sachs sold 5,870,393 Novo Nordisk shares in Q1 2026, an estimated $278M.
  • Novo Nordisk made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #707 holding.
  • Goldman Sachs first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Novo Nordisk position peaked at $663M in Q1 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.